Nephrogenic Systemic Fibrosis
8
0
0
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
1 terminated out of 8 trials
83.3%
-3.2% vs benchmark
25%
2 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis
Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels
Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)
Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR
Nephrogenic Systemic Fibrosis With Gadollinum
Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec
Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis